FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Lorazepam Injection
Status: Currently in Shortage
»Date first posted: 05/03/2018
»Therapeutic Categories: Neurology

Akorn Pharmaceuticals (Revised 03/01/2023)

Company Contact Information:
800-932-5676

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Lorazepam Injection 2 mg/mL (NDC 17478-040-01)	Not available	No new manufacturing of product

Amphastar Pharmaceuticals, Inc./IMS (Reverified 01/05/2023)

Company Contact Information:
800-423-4136

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
LORAZEPAM INJECTION, USP, C IV [2 mg/ mL](NDC 76329-8261-1)	Backorder due to the increase in demands		Other

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 10/13/2022)

Company Contact Information:
800-631-2174

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Ativan (lorazepam) Injection 2 mg/mL, 1 mL vial (NDC 0641-6001-25)	This presentation is temporarily on backorder.	Additional lots are scheduled for manufacturing and will be available in the October - November 2022 timeframe. Product will be made available as it is released.	Demand increase for the drug
Ativan (lorazepam) Injection 2 mg/mL, 10 mL vial (NDC 0641-6000-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 1 mL vial (NDC 0641-6003-25)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan (lorazepam) Injection 4 mg/mL, 10 mL vial ((NDC 0641-6002-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 1 mL vial (NDC 0641-6044-25)	This presentation is temporarily on backorder.	Additional lots are scheduled for manufacturing and will be available in the October - November 2022 timeframe. Product will be made available as it is released.	Demand increase for the drug
Lorazepam Injection, USP 2 mg/mL, 10 mL vial (NDC 0641-6046-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 1 mL vial (NDC 0641-6045-25)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Lorazepam Injection, USP 4 mg/mL, 10 mL vial (NDC 0641-6002-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug

Hospira, Inc., a Pfizer company (Revised 03/17/2023)

Company Contact Information:
844-646-4398

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
2 mg/mL; Carpuject Luer Lock Glass Syringe (NDC 00409-1985-30)	Available		Other
2 mg/mL; 1 mL Multiple Dose Glass Fliptop Vial (NDC 00409-6778-02)	Discontinued		Discontinuation of the manufacture of the drug